
    
      This is a randomized, double-blind, placebo-controlled study that will assess the safety
      efficacy and pharmacokinetics (PK) of miricorilant in patients with presumed Nonalcoholic
      Steatohepatitis (NASH).

      Patients who meet the criteria for the Study CORT118335-860 will be randomized on Day 1 to
      receive 900 mg miricorilant, 600 mg miricorilant, or placebo for 12 weeks.
    
  